Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-10-25
2009-08-11
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S193100, C424S198100, C435S069100, C536S023400, C536S023510, C536S023740
Reexamination Certificate
active
07572451
ABSTRACT:
The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a GIP protein or a GIP fragment linked to the VLP. The invention also provides a method for producing the aforesaid composition. The compositions of this invention are useful in the production of immunogens, in particular, for the prevention and/or treatment of obesity and hereby, in particular, by inducing efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. Accordingly, the invention further provides for methods of treating and/or preventing obesity and other conditions.
REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4918166 (1990-04-01), Kingsman et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 5928647 (1999-07-01), Rock
patent: 6004763 (1999-12-01), Gengoux et al.
patent: 6054312 (2000-04-01), Larocca et al.
patent: 6159728 (2000-12-01), Stockley et al.
patent: 6548651 (2003-04-01), Nielsen et al.
patent: 2002/0064533 (2002-05-01), Murray
patent: 2002/0081295 (2002-06-01), Schiller et al.
patent: 2002/0193565 (2002-12-01), Stanley et al.
patent: 2003/0054010 (2003-03-01), Sebbel et al.
patent: 2003/0175290 (2003-09-01), Renner et al.
patent: 2004/0076611 (2004-04-01), Bachmann et al.
patent: 2004/0076645 (2004-04-01), Bachmann et al.
patent: 2005/0191317 (2005-09-01), Bachmann et al.
patent: 2005/0272652 (2005-12-01), Gault et al.
patent: 0 479 210 (1992-04-01), None
patent: 1 171 465 (2002-01-01), None
patent: WO 99/08708 (1999-02-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 00/20592 (2000-04-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 00/32227 (2000-06-01), None
patent: WO 00/58360 (2000-10-01), None
patent: WO 01/85208 (2001-11-01), None
patent: WO 02/10195 (2002-02-01), None
patent: WO 02/094124 (2002-11-01), None
patent: WO 03/030946 (2003-04-01), None
patent: WO 03/060071 (2003-07-01), None
patent: WO 03/103697 (2003-12-01), None
patent: WO-2004/004761 (2004-01-01), None
patent: WO-2004/007538 (2004-01-01), None
patent: WO/2004/009116 (2004-01-01), None
patent: WO-2004/009124 (2004-01-01), None
patent: WO/2004/003143 (2004-08-01), None
patent: WO 2005/082928 (2005-09-01), None
patent: WO 2006/032674 (2006-03-01), None
Hu, et al. Chimeric Infectious Bursal Disease Virus-Like Particles Expressed In Insect Cells and Purified by Immobilized Metal Affinity Chromatography, Biotech. Bioeng. 1999 63(6): 722-730.
Gatto, et al. Rapid Response of Marginal Zone B Cells to Viral Particles. J Immunol. 2004, 173:4308-4316.
Hofmann and Muir Recent advances in the application of expressed protein ligation to protein engineering. Curr Opin Biotech 2002, 13:297-303.
Miyawaki, et al., Inhibition of gastric inhibitory polypeptide signaling prevents obesity. NATURE MEDICINE. 2002; 8(7):738-742.
Zorrilla, et al. Vaccination against weight gain. PNAS. 2006; 103(35): 13226-13231.
Neel, JV. The “thrifty genotype” in 1998. Nutrition Reviews; May 1999; 57, 5;S2-S9.
Fulurija, et al. Vaccination against GIP for the Treatment of Obesity. PLoS One. 2008; 3(9):e3163,1-11.
Bachmann, MF, Zinkernagel, RMThe influence of virus structure on antibody responses and virus serotype formation. Immunol Today, vol. 17(12) pp. 553-558, Elsevier Science Publishers, 1996.
Brown, WL, Mastico, RA, Wu, M, Heal , KG, Adams, CJ, Murray, JB, Simpson, JC, Lord, JM, Taylor-Robinson, AW, Stockley, PGRNA bacteriophage capsid-mediated drug delivery and epitope presentation. Intervirology, vol. 45(4-6) pp. 371-380, Karger, Jan. 2002.
Fehr, T, Skrastina, D, Pumpens, P, Zinkernagel, RMT cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc Natl Acad Sci U S A, vol. 95(16) pp. 9477-9481, National Academy of Sciences, 1998.
Fulurija, A, Lutz, TA, Sladko, K, Osto, M, Wielinga, PY, Bachmann, MF, Saudan, PVaccination against GIP for the Treatment of Obesity. PLoS One, vol. 3(9) pp. e3l63, Public Library of Science, Jan. 2008.
Jegerlehner, A, Tissot, A, Lechner, F, Sebbel, P, Erdmann, I, Kündig, T. BÃchi, T, Storni, T, Jennings, G, Pumpens, P, Renner, WA, Bachmann, MFA molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses, Vaccine, vol. 20(25-26) pp. 3104-3112, Elsevier Science, Aug. 2002.
Kozlovska, TM, Cielens, i, DreilinÅ+a, D, Dislers, A, Baumanis, V, Ose, V, Pumpens, PRecombinant RNA phage Q beta capsid particles synthesized and self-assembled in Escherichia coli. Gene, vol. 137(1) pp. 133-137, Elsevier/North-Holland, 1993.
Klovins, J. Overbeek, GP, van den Worm, SH, Ackermann, HW, van Duin, JNucleotide sequence of a ssRNA phage from Acinetobacter: kinship to coliphages. J Gen Virol, vol. 83(Pt 6) pp. 1523-1533, Society For General Microbiology, Jun. 2002.
Lechner, F, Jegerlehner, A, Tissot, AC, Maurer, P, Sebbel, P, Renner, WA, Jennings, GT, Bachmann, MFVirus-like particles as a modular system for novel vaccines. Intervirology, vol. 45(4-6) pp. 212-217, Karger, Jan. 2002.
Loktev, VB, Ilyichev, AA, Eroshkin, AM, Karpenko, LI, Pokrovsky, AG, Pereboev, AV, Svyatchenko, VA, Ignat'ev, GM, Smolina, MI, Melamed, NV, Lebedeva, CD, Sandakhchiev, LSDesign of immunogens as components of a new generation of molecular vaccines. J Biotechnol, vol. 44(1-3) pp. 129-137, Elsevier Science Publishers, 1996.
Nieland, JD, Da Silva, DM, Velders, MP, de Visser, KE, Schiller, JT, Müller, M, Kast, WM “Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response,” J Cell Biochem, vol. 73(2) pp. 145-152, Wiley, 1999.
Stoll, E, Wilson, KJ, Reiser, J, Weissmann, CRevised amino acid sequence of Qbeta coat protein between positions 1 and 60. J Biol Chem, vol. 252(3) pp. 990-993, American Society for Biochemistry and Molecular Biology 1977.
Voronkova, T, Grosch, A, Kazaks, A, Ose, V, Skrastina, D, Sasnauskas, K, Jandrig, B, Arnold, W, Scherneck, S, Pumpens, P, Ulrich, RChimeric bacteriophage fr virus-like particles harboring the immunodominant C-terminal region of hamster polyomavirus VP1 induce a strong VP1-specific antibody response in rabbits and mice. Viral Immunol, vol. 15(4) pp. 627-643, Mary Ann Liebert, Inc., Jan. 2002.
Zorrilla, EP, Iwasaki, S, Moss, JA, Chang, J, Otsuji, J, Inoue, K, Meijler, MM, Janda, KDVaccination against weight gain. Proc Natl Acad Sci U S A, vol. 103(35) pp. 13226-13231, National Academy of Sciences, Aug. 2006.
Baba, A.S.H., et al., “Effects of gastric inhibitory polypeptide, somatostatin and epidermal growth factor on lipogenesis in ovine adipose explants,”Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 127:173-82, Elsevier Science Inc. (2000).
Ballinger, A., “Gastric inhibitory polypeptide links overnutrition to obesity,”Gut 52:319-20, British Medical Ass. (2003).
Brown, J.C., et al., “Preparation of highly active enterogastrone,”Can. J. Physiol. Pharmacol. 47:113-114, NRC Research Paper (1969).
Brubaker, P.L. and Drucker, D.J. “Structure-Function of the Glucagon Receptor Family of G Protein-Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors,”Recept. Channels 8:179-188, Taylor & Francis (2002).
Chackerian, B., et al., “Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles,”Proc. Natl. Acad. Sci. USA 96:2373-2378, Medical Sciences (1999).
Creutzfeldt, W. and Ebert, R., “New developments in the incretin concept,”Diabetologia 28:565-573, Springer-Verlag (1985).
D'Alessio, D.A., et al., “Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairme
Bachmann Martin F.
Fulurija Alma
Saudan Philippe
Cytos Biotechnology AG
Mosher Mary E
Snyder Stuart W
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Gastric inhibitory polypeptide (GIP) antigen arrays and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gastric inhibitory polypeptide (GIP) antigen arrays and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gastric inhibitory polypeptide (GIP) antigen arrays and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4103561